Jacqueline M. Lamour
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jacqueline M. Lamour has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Daphne T. Hsu
Children’s Hospital at Montefiore, Bronx, NY (D.T.H.).
6 shared publications Elizabeth D. Blume
Department of Pediatric Cardiology, Boston Children's Hospital, Boston, Massachusetts
2 shared publicationsKimberly D. Beddows
2 shared publicationsLinda J. Addonizio
Division of Pediatric Cardiology, Columbia University, Morgan Stanley Children’s Hospital of New York at the Columbia University Medical Center, New York, USA
2 shared publicationsMarc E. Richmond
Division of Pediatric Cardiology, Columbia University, Morgan Stanley Children’s Hospital of New York at the Columbia University Medical Center, New York, USA
2 shared publications- Nida Siddiqi
Department of Pharmacy, Children's Hospital at Montefiore, Bronx, NY, USA
2 shared publications
Latest Publications
- 1 January 2019
- Published by Elsevier
- p. 852-867.e6
Pediatric Heart Failure and Pediatric Cardiomyopathies
- 1 January 2019
- Published by Elsevier
- p. 852-867.e6
Pediatric Heart Failure and Pediatric Cardiomyopathies
- 11 December 2018
- Published by Springer Nature
- p. 97-116
Pediatric Cardiac Transplantation and Mechanical Assist Devices
- 11 December 2018
- Published by Springer Nature
- p. 97-116
Pediatric Cardiac Transplantation and Mechanical Assist Devices
- 17 June 2015
- Published by Wiley in Pediatric Transplantation
- Vol. 19 (6) , 618-622
The effect of MMF dose and trough levels on adverse effects in pediatric heart transplant recipients
Limited pharmacokinetic and safety data exist for MMF in pediatric HTR. Previously targeted MPA-TL are 1.5-3.0 μg/mL. The objective of this study was to assess the outcomes targeting MPA-TL of 0.8-2.0 μg/mL in pediatric HTR. MPA-TL were retrospectively collected 2-12 months post-transplant. Acute rejection, infection, leukopenia, and GI complaints were then correlated with MPA-TL. A total of 355 MPA-TL from 22 HTR were included. Median age was 2.5 yr. Primary indication for transplant was dilated cardiomyopathy (64%). Mean MPA-TL was 1.7 ± 0.9 μg/mL. African American patients received significantly higher doses (702 ± 235 mg/m(2) ) compared with other races (p = 0.035). Leukopenia was less common in patients with SUB MPA vs. others (p = 0.01). MMF was discontinued for GI complaints in one patient and leukopenia in two patients. One SUB patient had acute rejection, and one SUP patient had infection. One-yr survival was 100%. Targeting a lower range for MPA-TL was not associated with significant rejection or infection. Despite lower MPA-TL, MMF was discontinued in 3/22 patients for adverse effects.
- 17 June 2015
- Published by Wiley in Pediatric Transplantation
- Vol. 19 (6) , 618-622
The effect of MMF dose and trough levels on adverse effects in pediatric heart transplant recipients
Limited pharmacokinetic and safety data exist for MMF in pediatric HTR. Previously targeted MPA-TL are 1.5-3.0 μg/mL. The objective of this study was to assess the outcomes targeting MPA-TL of 0.8-2.0 μg/mL in pediatric HTR. MPA-TL were retrospectively collected 2-12 months post-transplant. Acute rejection, infection, leukopenia, and GI complaints were then correlated with MPA-TL. A total of 355 MPA-TL from 22 HTR were included. Median age was 2.5 yr. Primary indication for transplant was dilated cardiomyopathy (64%). Mean MPA-TL was 1.7 ± 0.9 μg/mL. African American patients received significantly higher doses (702 ± 235 mg/m(2) ) compared with other races (p = 0.035). Leukopenia was less common in patients with SUB MPA vs. others (p = 0.01). MMF was discontinued for GI complaints in one patient and leukopenia in two patients. One SUB patient had acute rejection, and one SUP patient had infection. One-yr survival was 100%. Targeting a lower range for MPA-TL was not associated with significant rejection or infection. Despite lower MPA-TL, MMF was discontinued in 3/22 patients for adverse effects.
- 9 February 2014
- Published by Springer Nature in Pediatric Cardiology
- Vol. 35 (6) , 922-927
Reverse Ventricular Remodeling and Improved Ventricular Compliance After Heart Transplantation in Infants and Young Children
After heart transplantation (HT) in infants and young children, environmental and intrinsic factors may lead to changes in the geometry and compliance of the donor heart. Serial demographic, clinical, hemodynamic, and echocardiographic data were obtained from HT recipients younger than 4 years of age. Echocardiographic chamber measurement z-scores were compared using recipient body surface area from the time of HT to 1 week, 3 months, and last follow-up visit. Left ventricular end-diastolic volume (LVEDV) z-scores were correlated with pulmonary capillary wedge pressure (PCWP) at each time point. Heart transplantation was performed for 13 children between March 2009 and December 2012, 9 of whom (69 %) were boys. The median age at HT was 8 months (range, 4–43 months), and the mean follow-up period was 13 ± 7 months. Left ventricular end-diastolic dimension z-scores decreased significantly (p = 0.03) between HT and 1 week, then increased from 1 week to 3 and 12 months. (−1.32 ± 1.7, −0.71 ± 1.8, 0.41 ± 2.1, 0.79 ± 2.3, respectively). A positive relationship (R 2 = 0.48) between the LVEDV z-score and PCPW was present at the last follow-up visit. For infants and young children, the allograft demonstrates appropriate growth by 1 year after HT. Left ventricular compliance improves over time.
- 9 February 2014
- Published by Springer Nature in Pediatric Cardiology
- Vol. 35 (6) , 922-927
Reverse Ventricular Remodeling and Improved Ventricular Compliance After Heart Transplantation in Infants and Young Children
After heart transplantation (HT) in infants and young children, environmental and intrinsic factors may lead to changes in the geometry and compliance of the donor heart. Serial demographic, clinical, hemodynamic, and echocardiographic data were obtained from HT recipients younger than 4 years of age. Echocardiographic chamber measurement z-scores were compared using recipient body surface area from the time of HT to 1 week, 3 months, and last follow-up visit. Left ventricular end-diastolic volume (LVEDV) z-scores were correlated with pulmonary capillary wedge pressure (PCWP) at each time point. Heart transplantation was performed for 13 children between March 2009 and December 2012, 9 of whom (69 %) were boys. The median age at HT was 8 months (range, 4–43 months), and the mean follow-up period was 13 ± 7 months. Left ventricular end-diastolic dimension z-scores decreased significantly (p = 0.03) between HT and 1 week, then increased from 1 week to 3 and 12 months. (−1.32 ± 1.7, −0.71 ± 1.8, 0.41 ± 2.1, 0.79 ± 2.3, respectively). A positive relationship (R 2 = 0.48) between the LVEDV z-score and PCPW was present at the last follow-up visit. For infants and young children, the allograft demonstrates appropriate growth by 1 year after HT. Left ventricular compliance improves over time.
- 4 September 2011
- Published by Springer Nature in Pediatric Cardiology
- Vol. 33 (1) , 49-54
Multiple Risk Factors Before Pediatric Cardiac Transplantation Are Associated With Increased Graft Loss
Identification of heart transplant recipients at highest risk for a poor outcome could lead to improved posttransplantation survival. A chart review of primary heart transplantations from 1993 to 2006 was performed. Analysis was performed to evaluate the risk of graft loss for those with a transplantation age less than 1 year, congenital heart disease (CHD), elevated pulmonary vascular resistance (index > 6), positive panel reactive antibody or crossmatch, liver or renal dysfunction, mechanical ventilation, or mechanical circulatory support (MCS). Primary transplantation was performed for 189 patients. Among these patients, 37% had CHD, 23% had mechanical ventilation, and 6% had renal dysfunction. Overall graft survival was 82% at 1 year and 68% at 5 years. The univariate risk factors for graft loss included mechanical ventilation (hazard ratio [HR], 1.9; 95% confidence interval [CI], 1.15–3.18), CHD (HR, 1.68; 95% CI, 1.04–2.70), and renal dysfunction (HR, 3.05; 95% CI, 1.34–6.70). The multivariate predictors of graft loss were CHD (HR, 1.8; 95% CI, 1.02–2.64), mechanical ventilation (HR, 1.9; 95% CI, 1.13–3.10), and the presence of two or more statistically significant univariate risk factors (SRF) (HR, 3.8; 95% CI, 2.00–7.32). Mechanical ventilation, CHD, and the presence of two or more SRFs identify pediatric patients at higher risk for graft loss and should be considered in the management of children with end-stage heart failure.
- 4 September 2011
- Published by Springer Nature in Pediatric Cardiology
- Vol. 33 (1) , 49-54
Multiple Risk Factors Before Pediatric Cardiac Transplantation Are Associated With Increased Graft Loss
Identification of heart transplant recipients at highest risk for a poor outcome could lead to improved posttransplantation survival. A chart review of primary heart transplantations from 1993 to 2006 was performed. Analysis was performed to evaluate the risk of graft loss for those with a transplantation age less than 1 year, congenital heart disease (CHD), elevated pulmonary vascular resistance (index > 6), positive panel reactive antibody or crossmatch, liver or renal dysfunction, mechanical ventilation, or mechanical circulatory support (MCS). Primary transplantation was performed for 189 patients. Among these patients, 37% had CHD, 23% had mechanical ventilation, and 6% had renal dysfunction. Overall graft survival was 82% at 1 year and 68% at 5 years. The univariate risk factors for graft loss included mechanical ventilation (hazard ratio [HR], 1.9; 95% confidence interval [CI], 1.15–3.18), CHD (HR, 1.68; 95% CI, 1.04–2.70), and renal dysfunction (HR, 3.05; 95% CI, 1.34–6.70). The multivariate predictors of graft loss were CHD (HR, 1.8; 95% CI, 1.02–2.64), mechanical ventilation (HR, 1.9; 95% CI, 1.13–3.10), and the presence of two or more statistically significant univariate risk factors (SRF) (HR, 3.8; 95% CI, 2.00–7.32). Mechanical ventilation, CHD, and the presence of two or more SRFs identify pediatric patients at higher risk for graft loss and should be considered in the management of children with end-stage heart failure.
- Top Cited Papers
The Effect of Age, Diagnosis, and Previous Surgery in Children and Adults Undergoing Heart Transplantation for Congenital Heart Disease